Nimbus Therapeutics has entered into a multi-year research and licensing agreement with Eli Lilly to co-develop novel oral treatments for obesity and other metabolic disorders using artificial intelligence platforms. Under the deal, Nimbus will apply its computational drug design technology to identify small-molecule candidates, while Eli Lilly will fund research milestones and hold global commercialization rights. Up to $1.2 billion in potential payments, including research, development, regulatory and commercial milestones, could be earned by Nimbus. This collaboration expands Lilly’s metabolic pipeline beyond injectable therapies and underscores its strategic investment in next-generation weight-loss solutions.

Eli Lilly reported that tirzepatide products generated over $10 billion in combined sales during the latest quarter, contributing to a 54% year-over-year rise in total revenues. These medicines, approved for both type 2 diabetes and chronic weight management, have now been prescribed to more than 300,000 patients worldwide since their launches in 2022 and 2023. Gross margin remains robust at approximately 83%, while the company maintained its quarterly dividend, yielding 0.6%. Shares have climbed nearly 200% over the past three years as investors prize the blend of pharmaceutical stability and high growth.

Lilly is vying with Novo Nordisk for leadership in the expanding weight-loss market, projected by analysts to approach $100 billion annually by 2030. In a head-to-head study, Lilly’s injectable candidate demonstrated superior efficacy over Novo’s product, reducing body weight by an additional 2% on average. Furthermore, Lilly has submitted an oral weight-loss pill that would not require dietary restrictions, potentially offering a unique selling point against Novo’s recently approved tablet. Additional pipeline programs targeting metabolic pathways are in Phase 1, positioning the company for sustained growth beyond current blockbusters.